Here are the 10-Q quarterly reports from Quantum Cyber N.V. (QUCY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QUCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QUCY filings page.
Quantum Cyber N.V. (QUCY) reported a sharp increase in losses while executing a major strategic pivot. For the six months ended June 30, 2026, the company generated no revenue from continuing operations and recorded a net loss of $16.1 million, nearly double the prior-year period, driven by higher R&D and stock-based compensation tied to its new quantum drones and cybersecurity focus.
Total operating expenses from continuing operations rose to $12.4 million, including $4.3 million of in‑process R&D expense for a quantum antenna license from LightShift and increased general and administrative costs for new leadership and staff. The legacy colorectal cancer screening business was classified as discontinued operations and largely exited via asset sales totaling $1.6 million.
Liquidity improved: cash increased to $13.5 million from $0.9 million, mainly from $22.2 million of financing inflows, including preferred share issuances and warrant exercises. However, with an accumulated deficit of about $121.0 million and continued operating cash use of $9.9 million in the half‑year, management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern, and its plans depend on executing the new business model and securing further funding.
Quantum Cyber N.V. reported a net loss of $5.1 million for the quarter ended March 31, 2026, similar to the prior-year loss of $5.0 million. Continuing operations generated no revenue, while discontinued colorectal cancer activities produced $170,105 in revenue before being classified as held for sale.
Total operating expenses from continuing operations were $2.46 million, driven mainly by $2.12 million in general and administrative costs, including significant share-based compensation. The company ended the quarter with cash of $4.75 million and shareholders’ equity of $4.59 million, helped by $6.0 million of preferred share funding and $2.1 million from ordinary share issuances.
Management states that recurring losses, a large accumulated deficit of about $110 million, and limited revenue create “substantial doubt” about the ability to continue as a going concern. Strategically, Quantum Cyber has exited colorectal cancer screening, is focusing on its pancreatic cancer program, and is expanding into post‑quantum cybersecurity, including a subsequent license deal requiring up to $5.0 million in cash and 20 million shares, plus 5 million shares for an advisor, subject to conditions.